OS Therapies Announces Formation of Osteosarcoma Patient Advocacy Advisory Board OS Therapies, a biopharmaceutical company specializing in cancer immunotherapy and Antibody Drug Conjugates (ADCs), has announced the establishment of a…
Coya Therapeutics, a clinical-stage biotechnology firm specializing in biologics to enhance regulatory T cell (Treg) function, will present data from its phase 2, double-blind, placebo-controlled study of interleukin-2 (IL-2) for…
Agilent has announced that it has received FDA approval for the MAGE-A4 IHC 1F9 pharmDx (SK032) as a diagnostic tool to identify patients with synovial sarcoma who may qualify for…
Puma Biotechnology, a biopharmaceutical company, has released its financial results for the second quarter ending June 30, 2024. Comparisons are made between Q2 2024 and Q2 2023, unless specified otherwise.…
Neurocrine Biosciences today announced its financial results for the second quarter ending June 30, 2024, and provided an update on its 2024 financial outlook. Dr. Kevin Gorman, Chief Executive Officer…
Labcorp reported strong revenue and EPS growth for the second quarter of 2024, reflecting significant momentum as the company progresses into the latter half of the year. Chairman and CEO…
Today, a groundbreaking environmental health impact initiative was announced to assist those most vulnerable to extreme weather events, which can exacerbate existing chronic conditions. Initially, the initiative will focus on…
Vertex Announces Q2 2024 Financial Results, Raises Full-Year Product Revenue Guidance Vertex today reported consolidated financial results for the second quarter ending June 30, 2024, and increased its full-year product…
AbbVie today announced the completion of its acquisition of Cerevel Therapeutics (NASDAQ: CERE), making Cerevel a part of AbbVie. “AbbVie’s acquisition of Cerevel strengthens our foundation in neuroscience and positions…
Lilly announced today positive topline results from the SUMMIT phase 3 clinical trial evaluating the safety and efficacy of tirzepatide injection (5 mg, 10 mg, or 15 mg) in adults…
BioNTech Announces Promising Phase 2 Results for mRNA Immunotherapy BNT111 in Advanced Melanoma BioNTech today revealed positive topline data from its ongoing Phase 2 clinical trial (EudraCT No.: 2020-002195-12; NCT04526899)…
WuXi AppTec Reports First Half 2024 Financial Results WuXi AppTec, a global leader in R&D and manufacturing services for the pharmaceutical and life sciences sectors, has announced its financial results…